GLP-1 drugs research: summary GLP1 drugs may move beyond diabetes and weight loss into multidisease therapies This could significantly increase the number and profile of users, including nonobese and older populations Innovations such as oral GLP1s may further accelerate uptake and accessibility For food and beverage, the shift needs to be watched closely to understand behaviour change, consumption patterns and nutritional needs GLP-1s started life as diabetes medications, then took the world by storm for treating obesity
Studies show a possible link between semaglutide and NAION, a rare condition that can cause sudden vision loss
depicts decrease, represents increase
Collaborative care models enhance lifestyle interventions by focusing on diet, exercise, and foot care, essential for preventing complications such as diabetic foot ulcers
Damaged or lifted seal, or a compromised stopper
Vy creatine c ph hp khi sit c khng